Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 5/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | PLEC | Q15149 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.52 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492896 | 0.99 | RNASEH1 (0.57) | RNASEH1MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL3494842 | 0.92 | MAPT (0.58) | RNASEH1MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL3494524 | 0.90 | POLB (0.54) | RNASEH1MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL3492746 | 0.90 | POLB (0.54) | RNASEH1MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL38376 | 0.90 | RNASEH1 (0.52) | RNASEH1MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL3492895 | 0.89 | RNASEH1 (0.51) | RNASEH1MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL21504938 | 0.88 | KMT2A (0.58) | RNASEH1MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL3492427 | 0.88 | KMT2A (0.60) | RNASEH1MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL3491415 | 0.88 | POLB (0.59) | RNASEH1MAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL3494852 | 0.87 | KMT2A (0.61) | MAPTALDH1A1KMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481399-A1 | METHODS FOR TREATMENT OF HEART FAILURE | Cardurion Pharmaceuticals, LLC (US) | 2019-05-15 | — | — | EP | claimed |
| WO-2018009899-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS, LLC (US) | 2018-01-11 | — | — | WO | claimed |
| US-9006253-B2 | Crystal of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-D]pyrimidine-6-carboxylic acid | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | claimed |
| EP-2594570-B1 | CRYSTAL OF THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2015-02-25 | — | — | EP | claimed |
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | claimed |
| US-20140235655-A1 | CRYSTAL OF THIENOPYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-08-21 | — | — | US | claimed |
| US-8748525-B2 | Polyester film and method of fabricating the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2014-06-10 | — | — | US | claimed |
| US-8748437-B2 | Crystal of 2-(3,4 dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothien[2,3-D]pyrimidine-6-carboxylic acid | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | claimed |
| EP-2594570-A1 | CRYSTAL OF THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | claimed |
| US-20130123279-A1 | CRYSTAL OF THIENOPYRIMIDINE DERIVATIVE | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-16 | — | — | US | claimed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | claimed |
| US-20210139499-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS LLC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210139499-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | CARDURION PHARMACEUTICALS LLC (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3781155-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | Cardurion Pharmaceuticals, LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| CN-112367989-A | Meglumine salts of thienopyrimidines | 卡都瑞恩医药有限责任公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235655-A1 | CRYSTAL OF THIENOPYRIMIDINE DERIVATIVE | PDE9A, PDE7A, PDE12 | RNASEH1 1759/4885MAPT 2304/4885ALDH1A1 633/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | RNASEH1 813/4885MAPT 1619/4885ALDH1A1 2303/4885 |
| US-20210139499-A1 | MEGLUMINE SALTS OF THIENOPYRIMIDINES | DPYD, TPMT, TYMP | RNASEH1 1071/4885MAPT 3198/4885ALDH1A1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.